Followers | 449 |
Posts | 41478 |
Boards Moderated | 5 |
Alias Born | 09/26/2009 |
Thursday, July 30, 2015 6:31:52 PM
EPGL and Novartis to Enter Discussions
IRVINE, Calif., July 30, 2015 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL) announced today that Novartis /Alcon executives have recently contacted the Company about discussing EPGL's electronic contact lens technologies. Discussions will begin as early as Monday, August 3, 2015. Novartis CEO Joe Jimenez has been quoted as saying that the coming electronic contact lens market could be worth tens of billions of dollars over the next several years. Novartis partnered with Google in 2014 to create "smart contact lenses" and has been very public about their desire to develop such contact lenses successfully.
As previously disclosed EPGL owns 100% of certain patents pending and jointly owns certain patents pending with CooperVision, Inc. EPGL also remains in negotiations with CooperVision, Inc. as well. "The technology speaks for itself and we intend to license it to all of the top companies, unless someone secures exclusivity," said Michael Hayes. "We expect to announce a deal in the near future with someone who is a leader in the ophthalmic or technology field. We are just at the beginning stages of the coming 'Vision Revolution' and things are beginning to heat up," Hayes added.
In an effort to be more specific about EPGL developments to the investment community, on August 3, 2015, EPGL will announce an innovative accessory device technology which every electronic contact lens wearer in the future could potentially need to own.
About EP Global Communications, Inc.
EP Global Communications, Inc. is an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS).
Recent NVS News
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) • PR Newswire (US) • 04/15/2024 06:00:00 PM
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer • GlobeNewswire Inc. • 04/11/2024 11:00:49 AM
- Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News • IH Market News • 04/10/2024 11:13:48 AM
- New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting • PR Newswire (US) • 04/06/2024 08:16:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/15/2024 09:15:21 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 02/06/2024 09:52:29 PM
- Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More • IH Market News • 02/06/2024 11:14:00 AM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 02/05/2024 10:06:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 07:18:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:44:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:43:49 PM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 01/31/2024 12:42:06 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/31/2024 12:38:06 PM
- Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More • IH Market News • 01/31/2024 11:28:17 AM
- Sandoz to Acquire Cimerli Business from Coherus for $170 Million • Dow Jones News • 01/22/2024 06:59:00 AM
- Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More • IH Market News • 01/12/2024 11:10:50 AM
- Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal • Dow Jones News • 01/11/2024 06:02:00 PM
- Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal • Dow Jones News • 01/08/2024 06:43:00 PM
- Novartis on Track for Record High Close -- Data Talk • Dow Jones News • 01/08/2024 03:41:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 11:13:40 AM
- Novartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia Trial • Dow Jones News • 01/08/2024 07:01:00 AM
- Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant • Dow Jones News • 01/05/2024 03:15:00 PM
- Voyager Therapeutics Shares Leap Premarket on Novartis Collaboration • Dow Jones News • 01/02/2024 12:46:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 11:05:07 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM